Dimethyl fumarate

Research use only, not for human use.

Dimethyl fumarate (DMF;BG-12) exerts anti-inflammatory and pro-metabolic effects in a variety of cell types.

Dimethyl fumarate (DMF;BG-12) exerts anti-inflammatory and pro-metabolic effects in a variety of cell types; an effective novel treatment for multiple sclerosis; activates the Nrf2 pathway and has been identified as a nicotinic acid receptor agonist in vitro.Multiple Sclerosis Approved.

Cell Viability Assay Cell Line:SGC-7901, HT29, HCT116 and CT26 cells Concentration:20 μM, 50 μM, 100 μM, 200?μM Incubation Time:24 hours Result:Reduced cell viability in SGC-7901, HT29, HCT116 and CT26 cancer cells.Western Blot Analysis Cell Line:CT26 cancer cells Concentration:100 μM Incubation Time:3 hours, 6 hours, 12 hours, 24 hours Result:Significantly activated JNK, p38 and ERK in CT26 cells after treatment from 3 to 24?h.

Animal Model:Male C57BL/6 mice (8-week-old)Dosage:50 mg/kg Administration:Oral gavage; daily; for 7 days Result:Was shown to upregulate mRNA and protein levels of Nrf2 and Nrf2-regulated cytoprotective genes.

DMF | BG-12

Nuclear Receptor/Transcription Factor

Keap1-Nrf2

KEAP1-Nrf2

Inflammation/Immunology

Multiple Sclerosis

624-49-7

144.1253

C6H8O4

>98% (HPLC)

DMSO: 9.6 mg/mL

O=C(OC)/C=C/C(OC)=O

2-Butenedioic acid (2E)-, 1,4-dimethyl ester

(-20℃)

With Ice Pack

≥ 2 years